颗粒物在无氧性皮肤炎中通过HDACs和费拉格林变化的作用
Yoon Jin Roh1, Kui Young Park1, Na Yeon Koo1
1Department of Dermatology, Chung-Ang University Hospital, Seoul 06973, Republic of Korea.
Journal of microbiology and biotechnology
|July 29, 2025
概括
暴露于颗粒物 (PM) 可能会通过引起影响菲拉格林 (FLG) 表达的表观遗传变化而使皮炎 (AD) 恶化. 一种HDAC抑制剂,三静氨酸A (TSA),在AD模型中显示出恢复FLG水平的潜力.
科学领域:
- 皮肤病学 皮肤病学
- 环境健康 环境健康
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 亚托皮炎 (AD) 涉及皮肤屏障功能障碍,通常与 filaggrin (FLG) 基因异常有关.
- 遗传因素有助于AD,但环境影响,如颗粒物 (PM) 也被怀疑.
- 众所周知,暴露于颗粒物会加剧AD,但潜在的机制,特别是表观遗传机制,需要进一步研究.
研究的目的:
- 调查PM诱导影响ADFLG表达的表观遗传修饰的假设.
- 评估基因组脱乙酶 (HDACs) 在AD中PM诱导的表观遗传变化的作用.
- 为了评估HDAC抑制剂,Trichostatin A (TSA) 的治疗潜力,在一个AD模型中与PM暴露.
主要方法:
- 使用qRT-PCR,西部涂抹和免疫光学来测量AD模型中的FLG和HDAC水平.
- 暴露细胞和体内AD模型对PM和/或IL-4/13 (AD中的关键细胞因子).
- 与HDAC抑制剂TSA同时处理的样本,观察其对FLG和HDAC水平的影响.
主要成果:
- PM和IL-4/13联合治疗降低了FLG水平,增加了HDAC3和HDAC6的表达.
- 与单独的PM或IL-4/13治疗相比,TSA治疗导致FLG显著恢复和改变HDAC水平.
- 在PM暴露的体外和体内AD模型中观察到FLG和HDAC的变化.
结论:
- 暴露于颗粒物可以诱导表观遗传变化,通过影响FLG表达来促进AD病原体.
- TSA显示了改善PM诱导的FLG在AD中的表观遗传效应的潜力.
- 抑制HDAC是一种有前途的治疗策略,用于管理PM恶化的皮炎.
相关概念视频
01:20Asthma: Pathogenesis and Management
597
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
597
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
02:06Allergic Reactions
28.7K
Overview
28.7K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464
01:29Asthma-I: Introduction
2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
01:19Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482